Tirzepatide Dosing in Units: Separating Fact from Misconception

The biggest misconception: that tirzepatide doses are measured like insulin

Insulin has been measured in "units" for decades, and millions of people are familiar with drawing up 10, 20, or 40 units into a syringe. Because tirzepatide is also a subcutaneous injection, it is easy to assume the same measurement system applies. It does not.

The Mounjaro KwikPen (the only licensed tirzepatide formulation in the UK) contains a factory-set volume of drug in a pre-filled cartridge. You press the button once and the pen delivers the full dose. There is no window showing units, no plunger to push to a specific mark. The dose is expressed in milligrams: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg, with each pen containing four weekly doses at its labelled strength.

The reason tirzepatide dosing in units comes up at all is largely the growth of compounded or grey-market tirzepatide, where a powder or solution is drawn into an insulin syringe and the person injecting has to calculate how many units corresponds to a desired milligram dose. This is a very different situation from using a licensed pen, and one that carries its own set of risks. Understanding that difference is the starting point for any honest conversation about this topic. The tirzepatide overview page sets out how the licensed medicine works in the UK.

What the milligram schedule actually looks like, and who sets it

Treatment with licensed tirzepatide begins at 2.5 mg weekly. That first pen's job is to let your system adjust; nausea and other gastrointestinal effects are most common in the early weeks, and starting low reduces their severity. After four weeks, a prescriber reviews tolerability and, if appropriate, moves you to 5 mg. The schedule continues in 2.5 mg steps at roughly four-week intervals, up to a maximum of 15 mg.

Crucially, the prescriber decides each step. They consider how well you have tolerated the current dose, whether you have lost at least the expected amount of weight, and whether any symptoms warrant a pause or slower progression. Patients do not self-escalate. If you are working through the titration schedule and want to understand the clinical reasoning behind each step, the tirzepatide dosing page covers the full schedule in plain language.

The NHS patient information for tirzepatide, available on the NHS medicines page for tirzepatide, confirms this structure and explains what to do if you miss a dose, a question always best directed to your prescriber and the Patient Information Leaflet, not estimated independently.

One practical note: if you order before 12pm on a working day and receive clinical approval, your pen ships the same day. Worth factoring in around bank holidays or if payday falls on a Friday, plan your next order a day or two ahead.

When "units" does matter: compounded tirzepatide and why the distinction is serious

Outside the licensed supply chain, tirzepatide is sometimes sold as a compounded preparation, often as a vial of solution or a lyophilised powder for reconstitution. In these preparations, concentrations vary, and whoever is injecting has to calculate the volume (and therefore the number of syringe units) that corresponds to a target milligram dose.

This is where errors happen. A 100-unit insulin syringe holding 1 ml of solution at one concentration produces a completely different milligram dose if the concentration changes. Swap vials from different compounders, miscalculate the dilution, or misread the syringe, and the margin for dosing error is wide. The MHRA has warned publicly about counterfeit and unlicensed weight-loss preparations, and enforcement in 2025 included the first UK raid on an illicit manufacturing site producing fake tirzepatide pens. If you are looking at a preparation that requires you to measure units into a syringe, that is a strong signal it is not a licensed UK product. If you want to understand what tirzepatide 20 units means in practice and why that figure only arises outside the licensed pen system, that page explains the context clearly.

For a visual sense of how licensed tirzepatide doses map across the treatment journey, the tirzepatide dosing chart lays them out clearly. And if your question is specifically about how dosing relates to weight-loss outcomes at each strength, the dosing for weight loss page covers that ground in detail.

Eligibility for licensed tirzepatide and what the assessment covers

Licensed tirzepatide is available privately in the UK to adults with a BMI of 30 or above, or 27 and above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, dyslipidaemia, or obstructive sleep apnoea. Lower thresholds apply for some ethnic backgrounds under UK clinical guidance. BMI alone does not determine approval, the prescriber weighs the full clinical picture, including current medicines and relevant history.

NICE's appraisal of tirzepatide, TA1026, sets NHS eligibility criteria that are narrower than the licensed indications; private prescribing follows the licensed SmPC rather than NICE's NHS pathway, which is why some people access treatment privately while not yet qualifying on the NHS. The Mounjaro page explains both routes side by side.

A prescriber reviews every consultation at nume before any treatment is issued, a real clinician, working through the detail of your answers on the same day you submit them. If you want to understand how that process works in practice, our about us page sets out how the service is structured. When you are ready to see whether treatment is suitable for you, check your eligibility through a free consultation.